All News
More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK
Links:
Richard Conway RichardPAConway ( View Tweet)
Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c
Links:
Richard Conway RichardPAConway ( View Tweet)
Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b
Links:
Richard Conway RichardPAConway ( View Tweet)
Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B
Links:
Richard Conway RichardPAConway ( View Tweet)
@KDAO2011 @RheumNow Exactly: they asked general questions about what is important to patients - likelihood of success, tolerance, infectious risks as below.
@RheumNow https://t.co/DZieop9M45
Eric Dein ericdeinmd ( View Tweet)
van der Pol et al from BeST study. No association with diabetes for pred use HR 0.588 (95%CI 0.285; 1.21) nor cumulative pred dose OR 1.04 (95% CI 0.978; 1.13). Higher DAS assoc with diabetes. @RheumNow #EULAR2022 OP0272 https://t.co/QVjphcD7MG https://t.co/Buj8VAIJ5x
Links:
Richard Conway RichardPAConway ( View Tweet)
Increased risk of aortic regurgitation and atrial fibrillation in radiographic axSpA pts when compared to general population. No significant risk for AV block (II-III). Unclear if treatment affects cardiac risk in these patients.
@RheumNow #EULAR2022 ABST#POST0146
Robert B Chao, MD doctorRBC ( View Tweet)
Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S
Links:
Richard Conway RichardPAConway ( View Tweet)
Schett et al. CAR-T in SLE, case series 4 patients. Effective in inducing clinical remission in all 4 refractory patients. Looks like #rheummadness may have been (almost) correct @DavidLeverenz ! @RheumNow #EULAR2022 OP0279 https://t.co/frAU8COFs8
Links:
Richard Conway RichardPAConway ( View Tweet)
Do different therapies affect GCA PET scores differently?
n=47 LV-GCA pts, Padua, serial PET
(similar to prev @KQuinnRheum @petercgrayson work)
Need more protocolised data
but can't help but feel steroids alone doesn't quite touch the sides for GCA
POS0813 #EULAR2022 @RheumNow https://t.co/Y1sGmpNyDc
David Liew drdavidliew ( View Tweet)
In case there was doubt:
- steroid toxicity is real in GCA
- giving steroid-sparing therapies (TCZ, MTX) early makes a difference
just something to not forget when your next new GCA patient rolls in the door?
POS0805 #EULAR2022 @RheumNow https://t.co/2wGV3M8wZD
David Liew drdavidliew ( View Tweet)
COVID-19 mostly mild for majority of SpA patients.
Steroid use associated with more severe COVID-19 outcomes (OR 3.15).
TNFi found to be protective! (OR 0.26)
@RheumNow #EULAR2022 ABST#OP0254
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 Debate happening now:
📺⚕️Telemedicine: Salvation or necessary evil?
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Older age, HTN, dyslipidemia, CKD, cancer hx, and chronic liver disease co-morbidities increased risk of COVID19 severity. PMR was the only R-IMID identified and RTX tx also increased risk of severe COVID19. #EULAR2022 POS0203 @RheumNow https://t.co/TnhRnlWkX2
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2022 POS0196 found 9% of post-COVID19 patients developed MSK symptoms. @RheumNow https://t.co/YFT83TjXFL
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Yeoh @SuAnnYeoh1 @rheum_covid Factors assoc severe COVID outcomes in IIM. Age, male, high disease activity, 2+ comorbidities, pred>7.5mg, RTX, assoc hospitalisation or death @RheumNow #EULAR2022 OP0252 https://t.co/PvCeSX8UvF https://t.co/RaISpeUNsH
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 POS0199 showed marked decrease in SARS-CoV2 IgG ab 6 months after initial two dose vaccines. @RheumNow https://t.co/lZdWQUqFvf
Dr. Rachel Tate uptoTate ( View Tweet)
Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted effective fast acting Rx that could be used as monotherapy. @eular_org #EULAR2022 @RheumNow https://t.co/Gdel9YnAzA
Janet Pope Janetbirdope ( View Tweet)
More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf
TheDaoIndex KDAO2011 ( View Tweet)
Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb
TheDaoIndex KDAO2011 ( View Tweet)